As most CAR‐T‐treated patients have elevated serum IL‐6, anti‐IL‐6 (Siltuximab) and anti‐IL‐6R antibody (Tocilizumab) have been used to manage severe CRS (Riegler et al, 2019). This evidence concerns the gene IL6 and congenital rubella syndrome.